SCHEMBL10116893

SCHEMBL10116893

COc1ccc(C(=O)C2=C(O)C(=O)N(c3ccc(C(=O)N(C)C)cc3)C2c2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 11/20 0.68
KDM4E B2RXH2 4/20 0.55
HPGD P15428 1/20 0.55
RXFP1 Q9HBX9 4/20 0.54
CCR1 P32246 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HSD17B10 Q99714 2/20 0.53
GAA P10253 1/20 0.53
MEN1 O00255 1/20 0.52
LMNA P02545 1/20 0.52
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116926 0.89 KDM4E (0.69) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL10117149 0.87 RXFP1 (0.71) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL10117290 0.87 RXFP1 (0.71) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL392709 0.85 P2RX3 (0.62) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL391921 0.85 P2RX3 (0.59) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL10116895 0.84 P2RX3 (0.58) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL10116558 0.84 P2RX3 (0.57) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL10117195 0.84 P2RX3 (0.83) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL16384846 0.83 RXFP1 (0.59) P2RX3KDM4EHPGDRXFP1CCR1
SCHEMBL388463 0.82 P2RX3 (0.55) P2RX3KDM4EHPGDRXFP1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497263-B2 Pyrrolinone derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2013-07-30 US disclosed
US-8497263-B2 Pyrrolinone derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2013-07-30 US disclosed
US-8101644-B2 Pyrrolinone derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2012-01-24 US disclosed
US-8101644-B2 Pyrrolinone derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2012-01-24 US disclosed
US-20120010199-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KAI HIROYUKI (JP) 2012-01-12 US disclosed
US-20120010199-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KAI HIROYUKI (JP) 2012-01-12 US disclosed
US-20100210632-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2010-08-19 US disclosed
US-20100210632-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010199-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME P2RX3, P2RX2, P2RX1 P2RX3 1/4885KDM4E 3560/4885HPGD 2044/4885
US-20100210632-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME P2RX3, P2RX2, P2RX1 P2RX3 1/4885KDM4E 3560/4885HPGD 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.